Primary Care Vasculitis Polymyalgia Rheumatica and Giant Cell Arteritis

被引：2

作者：

Pioro, Mathilde H. ^{[1
,2
]}

机构：

[1] Cleveland Clin, Orthoped & Rheumatol Inst, Dept Rheumatol, 9500 Euclid Ave A50, Cleveland, OH 44195 USA

[2] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, 9500 Euclid Ave A50, Cleveland, OH 44195 USA

来源：

PRIMARY CARE | 2018年 / 45卷 / 02期

关键词：

Polymyalgia rheumatica; Giant cell arteritis; Temporal artery biopsy; Corticosteroids; Tocilizumab; SERONEGATIVE SYMMETRICAL SYNOVITIS; ERYTHROCYTE SEDIMENTATION-RATE; POSITRON-EMISSION-TOMOGRAPHY; PLACEBO-CONTROLLED TRIAL; PITTING EDEMA RS3PE; C-REACTIVE PROTEIN; DOUBLE-BLIND; TEMPORAL ARTERITIS; FOLLOW-UP; CLINICAL-FEATURES;

D O I：

10.1016/j.pop.2018.02.007

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory diseases of adults aged 50 years or older. The diagnosis of PMR is based on morning stiffness, proximal shoulder and pelvic girdle pain, and functional impairment. GCA is characterized by headache, jaw claudication, and visual disturbances. Constitutional symptoms and elevated inflammatory markers are common to both conditions. Temporal artery biopsy remains the gold standard for diagnosis of GCA. Glucocorticoids are the cornerstone of therapy, with tapering regimens individualized to the patient. Prompt diagnosis and treatment are essential to avert vision loss in GCA. Tocilizumab increases remission rates in GCA.

引用

页码：305 / +

页数：20

共 50 条

[31] Giant-Cell Arteritis and Polymyalgia Rheumatica
Sherwin, Justin C.
De Smit, Elisabeth
Hewitt, Alex W.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (17): : 1652 - 1652
[32] Epidemiology of Giant Cell Arteritis and Polymyalgia Rheumatica
Gonzalez-Gay, Miguel A.
Vazquez-Rodriguez, Tomas R.
Lopez-Diaz, Maria J.
Miranda-Filloy, Jose A.
Gonzalez-Juanatey, Carlos
Martin, Javier
Llorca, Javier
ARTHRITIS CARE & RESEARCH, 2009, 61 (10) : 1454 - 1461
[33] Polymyalgia rheumatica and giant-cell arteritis
Putschky, N
Zeidler, H
INTERNIST, 1997, 38 (09): : 887 - 897
[34] Giant-Cell Arteritis and Polymyalgia Rheumatica
Weyand, Cornelia M.
Goronzy, Joerg J.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (01): : 50 - 57
[35] Giant Cell Arteritis and Polymyalgia Rheumatica: an Update
Miguel A. González-Gay
Trinitario Pina
Current Rheumatology Reports, 2015, 17
[36] POLYMYALGIA RHEUMATICA AND GIANT-CELL ARTERITIS
JIPP, P
FEHRING, K
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1984, 109 (43) : 1635 - 1638
[37] Managing of giant cell arteritis and polymyalgia rheumatica
Gonzalez-Gay, Miguel A.
Castaneda, Santos
EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (11): : 1133 - 1144
[38] Management of giant cell arteritis and polymyalgia rheumatica
Meskimen, S
Cook, TD
Blake, RL
AMERICAN FAMILY PHYSICIAN, 2000, 61 (07) : 2061 - 2068
[39] Immunopathways in giant cell arteritis and polymyalgia rheumatica
Weyand, CM
Ma-Krupa, W
Goronzy, JJ
AUTOIMMUNITY REVIEWS, 2004, 3 (01) : 46 - 53
[40] Amyloidosis and Giant Cell Arteritis/Polymyalgia Rheumatica
Legault, Kimberly
Shroff, Anjali
Crowther, Mark
Khalidi, Nader
JOURNAL OF RHEUMATOLOGY, 2012, 39 (04) : 878 - 880

← 1 2 3 4 5 →